search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Supply chain & logistics


Root and branch Root and branch


Pharmaceutical companies were setting ambitious deadlines for improving supply chain sustainability prior to Covid-19. The pandemic has since laid bare their reliance on complex chains – many of them cold – that are signifi cant contributors to climate change. Lyn Eyb asks Kelley Hinds, head of sustainability and risk for Roche Global Procurement, Toby Peters, professor in cold economy, engineering and physical sciences at the University of Birmingham, and Ying Xie, head of economics, fi nance and law at Anglia Ruskin University, how pharma can shrink its footprint while increasing the supply of medicines.


ll industries need to address environmental degradation, but complex supply chains and tight regulation make climate policy particularly challenging for the pharmaceutical sector. Toby Peters, professor in cold economy, engineering and physical sciences at the University of Birmingham, is clear about the enormity of the challenge. “Cooling is the fastest growing driver of greenhouse gas emissions,” he says. “And, as we’ve seen with Covid-19, it underpins vaccine cold chains. With the world well off-track to limit warming to the


A 32


1.5°C objective of the Paris Agreement, Peters says small fixes won’t work – a radical approach is needed. He proposes a system of centralised “pack houses” or “cooling hubs” that would integrate the cold chains of all goods coming into a geographical area, including pharmaceuticals, agricultural and food products. It would work in a similar way to a shopping centre that has multiple outlets operating from a single, shared power supply.


This combined cooling demand would improve efficiencies, and allow for secondary systems and


World Pharmaceutical Frontiers / www.worldpharmaceuticals.net


Numstocker/www.shutterstock.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53